Non Small Cell Lung Cancer News and Research

RSS

Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.

Introgen announces additional broad patent in China

Introgen Therapeutics has announced that a patent with broad claims directed to combination therapy with the p53 gene and conventional chemotherapy or radiation was issued in China.

11 Aug 2005

Researchers identify protein called EMP-1 that is present in the tumors of patients who fail to respond to treatment with gefitinib

By the time the human genome was mapped, cancer researchers had already begun investigating the proteins that were encoded by these newly identified genes.

9 Aug 2005

Erlotinib increases survival in patients with advanced non-small cell lung cancer

An international clinical study led by Canadian researchers has demonstrated that a drug called erlotinib increases survival in patients with advanced non-small cell lung cancer who typically have no other treatment options.

13 Jul 2005

New clues about the location of genes potentially involved in the most common type of lung cancer

Using technology that makes it possible to zoom in on smaller sections of cell chromosomes than ever before, researchers at Dana-Farber Cancer Institute have identified nearly 100 chromosome regions where genes are either over-copied or missing in non-small cell lung cancer.

27 Jun 2005

Brief course of chemotherapy after surgery should be the new standard of care around the world

A Canadian national clinical trial has found that chemotherapy following surgery for early-stage non-small cell lung cancer significantly improves survival for the disease over just surgery alone.

27 Jun 2005

Double whammy of chemo plus surgery extends life for lung cancer patients

Recent research which has shown that chemotherapy can significantly lengthen life in many patients with lung cancer, has meant that doctors, for the first time in decades, have begun making major changes in the treatment of the disease.

23 Jun 2005

AstraZeneca announces U.S. labeling change to Iressa (gefitinib tablets)

AstraZeneca has announced that after discussions with the U.S. Food and Drug Administration (FDA), the company is making a labeling change to Iressa (gefitinib tablets).

19 Jun 2005

Study examines biomarkers for response to erlotinib in glioma

Researchers have found two biomarkers that, in patients with a malignant type of brain tumor called glioblastoma multiforme, were associated with response to the cancer drug erlotinib (Tarceva).

14 Jun 2005

Concurrent radiation, chemo, followed by surgery lengthens lung cancer patients' survival

Patients whose lung cancer has spread to the lymph nodes have a better chance of long-term survival if they receive combined modality therapy, such as concurrent radiation and chemotherapy followed by surgery, according to a study that Loyola University Health System’s Dr. Kathy S. Albain presented at the American Society of Clinical Oncology annual meeting.

18 May 2005

Study shows the longest reported survival rate for patients with locally advanced lung cancer

Five-year data from a study evaluating the use of docetaxel (Taxotere) administered after cisplatin/etoposide chemotherapy plus radiation therapy demonstrate the best long-term survival rates reported in patients with locally advanced (Stage IIIB) non-small cell lung cancer (NSCLC).

16 May 2005

Taxotere shows significant survival benefit in the treatment of advanced gastric cancer

Final results from the largest international study in the treatment of advanced stomach cancer, also known as gastric cancer, demonstrated that patients who received a Taxotere (docetaxel) Injection Concentrate-based chemotherapy regimen (Taxotere, cisplatin and 5-fluorouracil) had significantly improved overall survival rates compared to patients who received a standard treatment (cisplatin and 5- fluorouracil).

16 May 2005

Bevacizumab plus chemo extends survival beyond one year for large group of advanced lung cancer patients

Patients with a particular type of advanced lung cancer may have a new option based on data presented at the 2005 annual meeting of the American Society of Clinical Oncology showing that combining a drug that cuts off the cancer's blood supply with standard chemotherapy can shrink tumors and extend life.

15 May 2005

Hispanics have worse lung cancer survival rate

In a national population-based study of 16,036 lung cancer patients, Hispanics with curable stage I lung cancer had poorer lung cancer specific survival rates, as well as worse all-cause mortality, than a much larger group of white persons. Study results will appear in the second issue for May 2005 of the American Thoracic Society's peer-reviewed American Journal of Respiratory and Critical Care Medicine.

15 May 2005

Study identifies possible marker for efficacy of gefitinib in lung cancer patients

Patients with advanced non–small-cell lung cancer (NSCLC) whose tumor cells contain extra copies of the epidermal growth factor receptor (EGFR) gene may be more likely to respond to the drug gefitinib (Iressa), and this high gene copy number may be an effective predictor of gefitinib efficacy, according to a new study in the May 4 issue of the Journal of the National Cancer Institute.

3 May 2005

Researchers find ovarian cancer patients who appear to respond better than others to gefitinib, or Iressa

Researchers at Fox Chase Cancer Center in Philadelphia have identified a subset of ovarian cancer patients who appear to respond better than others to gefitinib, or Iressa. The research was presented today at the 96th Annual Meeting of the American Association for Cancer Research in Anaheim, Calif.

20 Apr 2005

Clinical trial of gefitinib for advanced lung cancer closes early

Researchers have closed a randomized clinical trial comparing gefitinib (Iressa) vs. placebo following chemotherapy and radiation for patients with non-small cell lung cancer (NSCLC) that had spread only to nearby tissues or lymph nodes. Review of interim data indicated that gefitinib would not improve survival.

19 Apr 2005

Drug combo gives lung cancer patients longer life

Preliminary results from a large randomized clinical trial, sponsored by the National Cancer Institute (NCI), by a network of researchers led by the Eastern Cooperative Oncology Group. Genentech, Inc., have shown that patients with previously untreated advanced non-squamous non-small cell lung cancer who received bevacizumab (Avastin) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.

15 Mar 2005

Bevacizumab (Avastin) in combination with standard chemotherapy helps advanced lung cancer sufferers

Preliminary results from a large, randomized clinical trial for patients with previously untreated advanced non-squamous, non-small cell lung cancer show that those patients who received bevacizumab (AvastinTM) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.

15 Mar 2005

Good results in new lung cancer treatment

Interim analysis of a Phase III study of Avastin (bevacizumab) with paclitaxel and carboplatin chemotherapies in first-line non-squamous, non-small cell lung cancer (NSCLC) met its primary goal of improving overall survival, or a reduction in the risk of death, compared to chemotherapy alone.

15 Mar 2005

Combining PET and CT scans leads to more accurate radiation therapy for lung cancer patients

Using Positron Emission Tomography in addition to Computed Tomography can reduce the amount of radiation exposure to normal tissue in some lung cancer patients

8 Mar 2005

Non Small Cell Lung Cancer News and Research

Introgen announces additional broad patent in China

Researchers identify protein called EMP-1 that is present in the tumors of patients who fail to respond to treatment with gefitinib

Erlotinib increases survival in patients with advanced non-small cell lung cancer

New clues about the location of genes potentially involved in the most common type of lung cancer

Brief course of chemotherapy after surgery should be the new standard of care around the world

Double whammy of chemo plus surgery extends life for lung cancer patients

AstraZeneca announces U.S. labeling change to Iressa (gefitinib tablets)

Study examines biomarkers for response to erlotinib in glioma

Concurrent radiation, chemo, followed by surgery lengthens lung cancer patients' survival

Study shows the longest reported survival rate for patients with locally advanced lung cancer

Taxotere shows significant survival benefit in the treatment of advanced gastric cancer

Bevacizumab plus chemo extends survival beyond one year for large group of advanced lung cancer patients

Hispanics have worse lung cancer survival rate

Study identifies possible marker for efficacy of gefitinib in lung cancer patients

Researchers find ovarian cancer patients who appear to respond better than others to gefitinib, or Iressa

Clinical trial of gefitinib for advanced lung cancer closes early

Drug combo gives lung cancer patients longer life

Bevacizumab (Avastin) in combination with standard chemotherapy helps advanced lung cancer sufferers

Good results in new lung cancer treatment

Combining PET and CT scans leads to more accurate radiation therapy for lung cancer patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News